))
Episode 52: Mark McDonough- President & CEO of ChromaCode
Manage episode 399570418 series 3526490
コンテンツは Vial によって提供されます。エピソード、グラフィック、ポッドキャストの説明を含むすべてのポッドキャスト コンテンツは、Vial またはそのポッドキャスト プラットフォーム パートナーによって直接アップロードされ、提供されます。誰かがあなたの著作物をあなたの許可なく使用していると思われる場合は、ここで概説されているプロセスに従うことができますhttps://ja.player.fm/legal。
Ever wondered how technology could drastically improve early detection in healthcare? Let us take you on a journey with Mark McDonough, President and CEO of ChromaCode, as we unfold the world of molecular diagnostics with a special focus on HDPCR technology. Mark, with his diverse background in the military and healthcare, brings a fresh perspective to the table. He shares his unique insights on leadership and the challenges that come with introducing ground-breaking technologies in a traditional industry.
First In Human is a biotech-focused podcast that interviews industry leaders and investors to learn about their journey to in-human clinical trials. Presented by Vial, a tech-enabled CRO, hosted by Simon Burns, CEO & Co-Founder. Episodes launch weekly on Tuesdays. To view the full transcript of this episode, click here.
Interested in being featured as a guest on First In Human? Please reach out to catie@vial.com.
🎧 Stay in the Loop!
For the latest news and updates, visit our website: https://vial.com
Follow us on social media for real-time insights:
Twitter: https://twitter.com/VialTrials
LinkedIn: https://www.linkedin.com/company/vialtrials
章
1. Episode 52: Mark McDonough- President & CEO of ChromaCode (00:00:00)
2. HD PCR Technology in Molecular Diagnostics (00:00:07)
3. Early Detection and Future Contributions (00:11:36)
62 つのエピソード
シェア
